Advertisement

Topics

BioPorto reports 20% increase in revenue growth for 1Q

06:15 EDT 9 May 2019 | Proactive Investors

BioPorto A/S (CPH:BIOPOR) CFO Ole Larsen tells Proactive Investors the Denmark-based company grew revenue by 20% to 5.5 million krones compared to 4.6 million krones last year.

Larsen says its continued focus on Research Use Only sales has doubled revenues from The NGAL Test in the US and sales of antibodies are positively affected by higher bulk orders.

Original Article: BioPorto reports 20% increase in revenue growth for 1Q

NEXT ARTICLE

More From BioPortfolio on "BioPorto reports 20% increase in revenue growth for 1Q"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...